Werbung
Werbung

EBS

EBS logo

Emergent Biosolutions, Inc.

12.97
USD
Gesponsert
-0.39
-2.94%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

13.16

+0.19
+1.48%

EBS Ergebnisberichte

Positives Überraschungsverhältnis

EBS übertreffen die 21 der letzten 40Schätzungen.

53%

Nächster Bericht

Datum des nächsten Berichts
02. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$219.68M
/
$0.11
Implizierte Änderung von Q3 25 (Revenue/ EPS)
-4.94%
/
-89.62%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+12.83%
/
+120.00%

Emergent Biosolutions, Inc. earnings per share and revenue

On 29. Okt. 2025, EBS reported earnings of 1.06 USD per share (EPS) for Q3 25, beating the estimate of -0.12 USD, resulting in a 974.59% surprise. Revenue reached 231.10 million, compared to an expected 195.94 million, with a 17.94% difference. The market reacted with a +36.60% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of 0.11 USD, with revenue projected to reach 219.68 million USD, implying an decrease of -89.62% EPS, and decrease of -4.94% in Revenue from the last quarter.
FAQ
For Q3 2025, Emergent Biosolutions, Inc. reported EPS of $1.06, beating estimates by 974.59%, and revenue of $231.10M, 17.94% above expectations.
The stock price moved up 36.6%, changed from $9.40 before the earnings release to $12.84 the day after.
The next earning report is scheduled for 02. März 2026.
Based on 4 analysts, Emergent Biosolutions, Inc. is expected to report EPS of $0.11 and revenue of $219.68M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung